Biosimilars in inflammatory bowel disease: Cost savings are welcome but evidence supporting equivalence of biosimilar and originator drugs is currently limited

Research output: Contribution to journalComment / DebateOtherpeer-review

1 Citation (Scopus)
Original languageEnglish
Pages (from-to)294-295
Number of pages2
JournalMedical Journal of Australia
Issue number7
Publication statusPublished - 3 Oct 2016

Cite this